<table>
<thead>
<tr>
<th>Alert</th>
<th>1000 mg magnesium sulfate = 98 mg elemental Mg = 4.1 mmol (8 mEq) of elemental Mg. 500 mg magnesium aspartate = 37.4 mg elemental Mg = 1.5 mmol (3 mEq) of elemental Mg. Intravenous doses should be diluted to a concentration of Mg 20% or less. Calcium chloride/calcium gluconate should be available to reverse adverse effects.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Action</td>
<td>Magnesium is an intracellular cation. Calcium and NMDA receptor antagonist. Magnesium is necessary for several steps in glycolysis, the Krebs cycle and in protein and nucleic acid synthesis. It is vital for normal energy storage and transfer. Magnesium plays an important role in neurochemical transmission, and is essential for proper neurochemical functioning. Magnesium has an anticonvulsant effect.</td>
</tr>
<tr>
<td>Drug Type</td>
<td>Electrolyte</td>
</tr>
<tr>
<td>Trade Name</td>
<td>DBL Magnesium Sulfate Concentrated Injection (Hospira) MagMin Tablets (Blackmores) Mag-Sup Tablets (Petrus)</td>
</tr>
<tr>
<td>Presentation</td>
<td>IV/IM: 50% magnesium sulfate 5 mL (2.47 g magnesium sulfate/5 mL) and 10 mL (5 g magnesium sulfate/10 mL) ampoules. PO: • MagMin 500 mg magnesium aspartate tablets. • Mag-Sup 500 mg magnesium aspartate tablets. 500 mg magnesium aspartate tablet contains 37.4 mg (1.5 mmol) of elemental Mg.</td>
</tr>
<tr>
<td>Dosage/Interval</td>
<td>Hypomagnesaemia 25–50 mg magnesium sulfate/kg IV infusion over 30–60 minutes. Repeat if necessary. Chronic hypomagnesaemia PO: 187 mg of elemental magnesium per m²/day in divided doses. (Endocrine team, personal email communication) (=2500 mg magnesium aspartate per m²/day)</td>
</tr>
<tr>
<td></td>
<td>Body Surface Area (BSA) calculation: [ BSA (m^2) = \sqrt{\frac{\text{height (cm)} \times \text{weight (kg)}}{3600}} ]</td>
</tr>
<tr>
<td></td>
<td>Pulmonary hypertension: Loading dose of 200 mg magnesium sulfate/kg IV over 60 minutes followed by continuous IV infusion 20–50 mg/kg/hour (target serum magnesium between 3.5 and 5.5 mmol/L) Perinatal asphyxia 250 mg magnesium sulfate/kg/dose of over 1 hour to be commenced within 6 hours of birth. Total 3 doses at 24 hour intervals. Torsades de pointes with pulse 25-50 mg magnesium sulfate/kg IV over 15–20 minutes. Pulseless torsades de pointes 25–50 mg magnesium sulfate/kg IV/Intraosseous (IO) over several minutes. Intramuscular Route (Emergency management of Neonatal tetany/convulsions/Hypocalcaemic convulsion when no IV access) IM: 100 mg magnesium sulfate/kg (0.2 mL/kg of 50% magnesium sulfate). Can be repeated 12 hourly.</td>
</tr>
<tr>
<td>Route</td>
<td>IV, IM, oral, Intraosseous.</td>
</tr>
<tr>
<td>Preparation/Dilution</td>
<td>Hypomagnesaemia/Torsades de pointes</td>
</tr>
</tbody>
</table>
Draw up 0.4 mL (200 mg of magnesium sulfate) of 50% solution and add 7.6 mL sodium chloride 0.9% or glucose 5% to make a final volume of 8 mL with a concentration of 25 mg/mL.

**Pulmonary hypertension IV infusion**
Loading dose: Draw up 2 mL (1000 mg of magnesium sulfate) of the 50% solution and add 8 mL of sodium chloride 0.9% or glucose 5% to give a final volume of 10 mL with a concentration of 100 mg/mL.

Maintenance infusion: Draw up 2 mL/kg (1000 mg/kg of magnesium sulfate) of 50% solution and add glucose 5% or sodium chloride 0.9% to make a final volume of 50 mL. Infusing at a rate of 1 mL/hour = 20 mg/kg/hour.

**Perinatal asphyxia**
Draw up 2 mL (1000 mg of magnesium sulfate) of the 50% solution and add 8 mL of sodium chloride 0.9% or glucose 5% to give a final volume of 10 mL with a concentration of 100 mg/mL.

**Administration**
- **IV bolus for hypomagnesaemia**: Infused over 30–60 minutes.
- **Loading dose for pulmonary hypertension**: Administer over 60 minutes.
- **IV dose for perinatal asphyxia**: Administer over 60 minutes.
- **Torsades de pointes**: Administer the preparation over several minutes to 20 minutes.

**Monitoring**
- ECG and continuous or frequent blood pressure. Monitor magnesium concentrations.

**Contraindications**
- Heart block or myocardial damage.

**Precautions**
- Use with caution in renal impairment.

**Drug Interactions**
- Concurrent use with paralysing agents may enhance neuromuscular blockade (e.g. succinylcholine, vecuronium, rocuronium, etc).
- Concomitant use with aminoglycosides may cause neuromuscular weakness (respiratory arrest).

**Adverse Reactions**
- Hypotension, bradycardia and circulatory collapse with rapid infusion.
- ECG changes (prolonged AV conduction time, sino-atrial block, AV block). Calcium chloride/calcium gluconate should be available to reverse adverse effects.
- Flushing, sweating, respiratory depression (particularly with higher plasma concentrations), abdominal distension, diarrhoea, urinary retention, CNS depression, muscle relaxation, hyporeflexia.

**Compatibility**
- Sodium chloride 0.9%, sodium chloride 0.45%/glucose 4%, glucose 5%, parenteral nutrition glucose amino acid solution.
- Y site: Aciclovir, amifostine, amikacin, ampicillin, aztreonam, bivalirudin, caspofungin, cefotaxime, cefoxitin, cefazolin, chloramphenicol, cisatracurium, dexamethasomide, doripenem, esmolol, gentamicin, granisetron, heparin sodium, hydrocortisone sodium succinate, labelatal, linezolid, metronidazole, milrinone, morphine sulfate, piperacillin-tazobactam (EDTA-free), potassium chloride, remifentanil, sodium nitroprusside, trimethoprim-sulfamethoxazole, vancomycin.

**Incompatibility**
- Fat emulsion. Incompatible with soluble phosphates and with alkaline carbonates and bicarbonates.
- Y site: Aminophylline, amiodarone, anidulafungin, azathioprine, calcium chloride, calcium salts, cefepime, ceftriaxone, ciprofloxacin, clindamycin, cyclosporin, dexamethasone, ganciclovir, haloperidol lactate, indometacin, methylprednisolone sodium succinate, pentamidine, phosphate salts, sodium bicarbonate.

**Stability**
- Change the IV preparation every 24 hours.

**Storage**
- Store at room temperature and protect from light.

**Special Comments**
- Serum Mg concentrations do not reflect whole body stores.
- Renally excreted.

**Evidence summary**
- Refer to full version.

**References**
- Refer to full version.